This report covers the present scenario and growth prospects of the global respiratory disposable devices market for 2016-2020. To calculate the market size, we consider the revenue generated from the sales of various respiratory disposable devices used during invasive and non-invasive surgical treatment and patient care.The report presents the vendor landscape and a corresponding detailed analysis of the top five vendors operating in the market. In addition, it discusses the major drivers influencing market growth and the challenges faced by vendors and the market as a whole. It also examines key emerging trends and their influence on current and futuremarket scenarios.

The medical and healthcare application segment is the largest segment of theglobal radiation detection products market with a market share of 66%. In the domestic security and military use application segment, domestic securitysub segment will grow at a CAGR of 7.16%. China is the leading country in APAC, driving the growth of the market for radiationdetection products used for a number of industrial applications like measuringnuclear radiation and handling nuclear wastes. Innovations in radiation detection materials continue to change the marketdynamics and profitability of vendors.

The global Pompe market is a monopolistic market led by Sanofi Genzyme with its two approved therapies, Myozyme and Lumizyme. Considering the rare nature of the disease, the pipeline also remains low and hence, Sanofi Genzyme is expected to continue with its market leadership position over the forecast period.The market has limited treatment options, which stand as a major growth hindrance. The impact gets magnified with the high costs associated with these available therapies. These factors work negatively toward patient adherence in an already small patient pool. However, the initiatives such as patient assistance program and favorable reimbursement policies by healthcare partners should be able to partially offset the combined impact of factors discussed above and help market overcome the existing challenges over next couple of years.

In this report, Technavio covers the present scenario and growth prospects of the global protein therapeutics market for 2017-2021 (base year: 2016; forecast year:2021). To calculate the market size, the report considers revenue generated from the sales of branded and biosimilar drugs used for the treatment of various diseases. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the patent expiries of the marketed drugs during the forecast period.

The demand for PD is high when compared to hemodialysis, as it is used more in the management of end-stage kidney or renal disease (ESRD). Today, peritoneal dialysis is considered one of the most efficient and cost-effective options for treating chronic kidney diseases at home through self-care.The demand for APD machines is on the rise when compared to CAPD, as they are portable and available in small size. They can be used during night and requires no frequent exchange of bag.This report covers the present scenario and the growth prospects of the global peritoneal dialysis market for the period 2016-2020. 

上周医药板块继续跑输大盘，我们对于医药板块整体维持相对谨慎判断，一方面，前4个月医保控费压力依然较大，在参保人数增长49%的情况下（两保合一及三保合一原因），基金支出只增长24%。另一方面，从医院终端数据来看，前3个月的增速仅有3.6%，创近几年新低。但是从结构上来看，部分治疗性的刚性用药保持较快增长，主要是中药注射剂和辅助用药下滑导致。因此，我们认为从投资上来讲也分开来看，优先考虑临床刚性需求的处方药的龙头企业，规避辅助用药与中药注射剂。

5月份wind全A股指数下跌2.9%，医药板块下跌2.6%，基本跑平市场。医药板块相对市场估值溢价率处于五年来新低。5月份股价表现比较好的个股主要为三类：（1）继续取得比较好市场表现的白马股；（2）大股东或者高管大幅度增持的个股；（3）一季度业绩超预期的个股。 

17 年 4 月 VK3 价格继续上涨， VB1 价格在高位微涨，VC 价格维持高位，在 4 月份均价 69.47 元/千克，环比上涨 28.08%，已在 70 元/千克高位维持近一个月。VE、VB2、VA 价格继续下滑；泛酸钙在 4 月均价环比上涨 3.11%，而最新报价又开始回调；总体来看去年整年维生素行情总体向好，部分品种价格显著提升，也有价格随后逐渐有所回落，长期来看，我们预计后续维生素品种价格大概率仍将延续分化。

VD3 价格蛰伏底部，短期底部震荡，长期有望迎来反弹。VD3 价格自 2016年以来经历了短暂时间的上涨，但是并未持续，价格一度达到 66.5 元/kg的历史低位，目前已小幅回调至 68 元/kg。VD3 价格自 2015 年以来长期处于历史低位，部分生产企业已处于持续亏损状态，已有产能收缩，新进产能不足。此外 VD3 龙头企业花园生物具备较强的技术和成本优势，自产 NF级胆固醇（合成 VD3 的原料）打通了 VD3 产业链上下游。虽然海盛化工、新和成等也具备 VD3 的生产能力，但是原料 NF 级胆固醇仍依赖采购。

本周医药板块跟随大盘小幅震荡，板块内个股活跃度依旧不高，在近期大盘盘整背景下，我们仍然建议投资者继续关注有业绩支撑的个股。

长春高新核心子公司金赛药业是国内生长激素龙头，生长激素占高新的营收、利润比例达 70%，受益弹性最大。金赛的生长激素产品梯队全球领先，包括粉针、水针以及 PEG 化长效剂型。安科生物目前生长激素粉针营收占比在 30%左右，另有水针和长效剂型处于临床试验阶段。